Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YQ23 Alone and with Pembrolizumab in Advanced Solid Tumors
NCT04513067Phase 1Terminated
- Sponsor
- New Beta Innovation
- Start
- Aug 2020
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of YQ23 in solid tumor (2 arms), sponsored by New Beta Innovation. Primary endpoints: Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) and Maximum Tolerated Dose. Started Aug 2020; status: terminated.
02
Drugs
YQ23
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04513067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513067.